Novartis may have insisted earlier this year that it hadn’t given up on anti-TIGIT checkpoint inhibitors, but, now, the Swiss Big Pharma seems to have had a change of heart. Having paid $300 million ...
BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody. The global biopharma had been evaluating ociperlimab, alongside ...
Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing. This ...
BeiGene lost its TIGIT inhibitor collaboration with Novartis but signed an antibody-drug conjugate deal with Duality Biologics. Takeda has pulled the FDA filing for its dengue vaccine after the FDA ...
Beigene Ltd. said it is shutting down development of its anti-TIGIT antibody, ociperlimab (BGB-A1217), after the humanized IgG1-variant monoclonal antibody failed a phase III trial in lung cancer. The ...
Effect of SLAMF8 on the phagocytosis of tumor-associated macrophages in colorectal cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...
From Roche Holding AG to Novartis AG, bad news abounds for anti-TIGIT immunotherapies. In an SEC filing on July 11, Chinese oncology R&D firm Beigene Ltd. and Basel, Switzerland-based Novartis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results